Parkinson's Disease Related Dementia Epidemiology Forecast 2025-2034

According to several population-based epidemiological studies, 20% to 40% of Parkinson’s disease patients develop dementia. Further, a 2024 study of the Parkinson's Progression Markers Initiative (PPMI) cohort showed a 9% to 15% probability of dementia at 10 years for 417 participants with Parkinson's disease. In the University of Pennsylvania (Penn) cohort, 389 participants had a 27% probability of dementia at 10 years. Parkinson’s disease related dementia epidemiology forecast suggests that as the number of individuals diagnosed with Parkinson's disease continues to rise, the prevalence of Parkinson’s disease related dementia is projected to increase in the coming years.

Parkinson’s Disease Related Dementia Epidemiology Forecast Report Coverage

The “Parkinson’s Disease Related Dementia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Parkinson’s disease related dementia. It projects the future incidence and prevalence rates of Parkinson’s disease related dementia cases across various populations. The study covers age and type as major determinants of the Parkinson’s disease related dementia population. The report highlights patterns in the prevalence of Parkinson’s disease related dementia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on Parkinson’s disease related dementia epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Parkinson’s Disease Related Dementia Understanding: Disease Overview

Parkinson’s disease related dementia (PDD) refers to a cognitive decline that occurs in some people with Parkinson’s disease (PD), a progressive neurodegenerative disorder that primarily affects movement. As the disease progresses, dementia can develop in some Parkinson's disease patients, which can impact memory, thinking, and behavior.

Parkinson’s disease related dementia typically develops in people who have had Parkinson’s disease for several years. The exact cause of Parkinson’s disease related dementia is believed to be related to the accumulation of abnormal proteins in the brain, such as alpha-synuclein. This accumulation affects the brain’s ability to function properly, leading to cognitive changes. Common symptoms of PDD include memory problems, difficulty concentrating, confusion, and changes in personality or behavior.

Parkinson’s Disease Related Dementia Epidemiology Perspective

The Parkinson’s disease related dementia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Parkinson’s disease related dementia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The Parkinson’s disease related dementia detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Various population-based epidemiological studies indicate that 20% to 40% of Parkinson’s disease patients develop dementia.
• In a 2024 study, participants from the Parkinson's Progression Markers Initiative (PPMI) cohort, including 417 individuals with Parkinson's disease, showed a 9% to 15% probability of dementia at 10 years of disease duration. In the University of Pennsylvania (Penn) cohort, 389 participants with Parkinson's disease had a 27% probability of Parkinson’s disease related dementia at 10 years, with 47% diagnosed by 15 years, and 74% by 20 years.
• The Alzheimer’s Association states that some studies indicate the average time from the onset of Parkinson's disease to the development of dementia is about 10 years.
• According to Johns Hopkins Medicine, Parkinson's disease initially causes physical symptoms, with cognitive issues like forgetfulness and concentration problems developing later. As the disease progresses, about 4 in 5 individuals are estimated to develop Parkinson’s disease related dementia.
• Several studies have reported that at least 75% of people with Parkinson's disease who live for more than 10 years will develop dementia.

Country-wise Parkinson’s Disease Related Dementia Epidemiology Segment

The Parkinson’s disease related dementia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Parkinson’s disease related dementia varies significantly between countries due to differences in factors such as the prevalence of Parkinson’s disease, genetic predisposition, healthcare access, and diagnostic capabilities. Further, environmental factors, lifestyle patterns, and comorbidities such as cardiovascular disease or diabetes can influence the incidence of Parkinson’s disease related dementia in various regions. According to the Parkinson's Foundation, about 1 million people in the United States are affected by Parkinson's disease. This number is projected to increase to 1.2 million by 2030, which indicates a likely rise in the prevalence of Parkinson’s disease related dementia.

Parkinson’s Disease Related Dementia: Treatment Overview

Parkinson’s disease related dementia therapeutics include cholinesterase inhibitors (rivastigmine and donepezil), which work by increasing levels of acetylcholine. These drugs may help improve cognitive function and reduce symptoms of dementia. Memantine is also used in patients experiencing moderate to severe dementia.

As depression is common in Parkinson’s disease related dementia, medications such as selective serotonin reuptake inhibitors (SSRIs) may be prescribed to help improve mood and emotional well-being. Atypical antipsychotics like quetiapine or clozapine are prescribed in Parkinson’s disease related dementia cases where patients experience hallucinations or delusions.

Key Questions Answered

• What are the key findings of Parkinson’s disease related dementia epidemiology in the 8 major markets?
• What will be the total number of patients with Parkinson’s disease related dementia across the 8 major markets during the forecast period?
• What was the country-wise Parkinson’s disease related dementia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of Parkinson’s disease related dementia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Parkinson’s disease related dementia during the forecast period of 2025-2034?
• What are the currently available treatments in the Parkinson’s disease related dementia market?
• What are the disease risks, signs, symptoms, and unmet needs of Parkinson’s disease related dementia?

Scope of the Parkinson’s Disease Related Dementia Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Parkinson’s disease related dementia based on several factors.
• The Parkinson’s Disease Related Dementia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Parkinson’s disease related dementia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.